Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension

Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherap...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of ophthalmology 2021-01, Vol.31 (1), p.103-111
Hauptverfasser:	Topouzis, Fotis, Goldberg, Ivan, Bell, Katharina, Tatham, Andrew J, Ridolfi, Antonia, Hubatsch, Douglas, Nicolela, Marcelo, Denis, Phillipe, Lerner, S Fabian
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic alpha-2 Receptor Agonists - adverse effects Adrenergic alpha-2 Receptor Agonists - therapeutic use Aged Aged, 80 and over Antihypertensive Agents - therapeutic use Brimonidine Tartrate - adverse effects Brimonidine Tartrate - therapeutic use Carbonic Anhydrase Inhibitors - adverse effects Carbonic Anhydrase Inhibitors - therapeutic use Double-Blind Method Drug Combinations Female Glaucoma, Open-Angle - drug therapy Glaucoma, Open-Angle - physiopathology Humans Intraocular Pressure - drug effects Intraocular Pressure - physiology Latanoprost - therapeutic use Male Middle Aged Ocular Hypertension - drug therapy Ocular Hypertension - physiopathology Original s Sulfonamides - adverse effects Sulfonamides - therapeutic use Thiazines - adverse effects Thiazines - therapeutic use Tonometry, Ocular Travoprost - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherapy. Methods: In this Phase 4, double-masked trial, patients aged ⩾18 years, with a mean intraocular pressure of ⩾19 and
ISSN:	1120-6721 1724-6016
DOI:	10.1177/1120672119878044